Halozyme Therapeutics Inc. HALO
$68.97
▼ -1.74% 24H
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monocl…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees423
TickerHALO
Statistics
Market Cap$8.17B
Revenue (TTM)$1.40B
Net Income$316.9M
Net Margin22.7%
EPS$2.56
P/E24.82
P/S5.56
P/B38.17
EV/EBITDA10.72
ROE99.4%
Dividend Yield—
Price$68.97
Data: Twelve Data · Revenue = mcap / P/S